The Centers for Medicare & Medicaid Services (CMS) has opened a crucial public comment period, inviting employers, benefits advisors, healthcare stakeholders, and the general public to contribute to the enhancement of the National Average Drug Acquisition Cost (NADAC) survey program. This initiative directly influences the reimbursement rates for prescription drugs across a vast spectrum of health plans, from state-administered Medicaid programs to a significant portion of employer-sponsored coverage, thereby impacting the out-of-pocket expenses for millions of Americans. The opportunity to provide feedback, detailed in a notice published in the Federal Register, presents a rare chance for stakeholders to shape a fundamental mechanism in the complex landscape of U.S. drug pricing.
Understanding the NADAC Program and Its Far-Reaching Impact
At its core, the NADAC program represents a cornerstone of transparency in an often-opaque pharmaceutical supply chain. Administered by CMS, it involves a monthly survey of approximately 72,000 pharmacies nationwide, meticulously collecting data on the true acquisition costs of prescription drugs. Unlike list prices or other theoretical benchmarks, NADAC aims to capture what pharmacies genuinely pay to acquire medications from wholesalers, providing a vital snapshot of the market’s underlying costs.
The data derived from these extensive monthly surveys serves multiple critical functions. Primarily, state Medicaid programs rely on NADAC results to establish accurate reimbursement rates for the medications dispensed to their participants. This ensures that state funds are disbursed efficiently and that pharmacies are adequately compensated for providing essential services to vulnerable populations. However, NADAC’s influence extends far beyond government-funded programs. A growing number of employer-sponsored health plans, either directly or indirectly, integrate NADAC data into their formulary design and reimbursement methodologies. By using a publicly available, transparent benchmark for drug acquisition costs, these plans seek to negotiate more favorable terms with Pharmacy Benefit Managers (PBMs) and ultimately reduce costs for both the plan sponsor and its members.
The importance of NADAC is amplified by the sheer scale of prescription drug spending in the United States. According to the National Health Expenditure Accounts (NHEA) by CMS, prescription drug spending reached an estimated $378 billion in 2021, representing approximately 8% of total national health expenditures. This figure is projected to continue its upward trajectory, driven by factors such as the introduction of high-cost specialty drugs, increased utilization, and overall price inflation. For employers, who bear a significant portion of healthcare costs for their workforce, managing prescription drug expenses is a top priority. Reports from industry analysts, such as PSG, project specialty drug costs to jump by as much as 32% by 2028, underscoring the urgent need for robust and reliable cost benchmarks like NADAC.
The Call for Public Comments: A Window of Opportunity
The current public comment period, which closes on November 2nd, invites stakeholders to offer insights on "ways to enhance the quality, utility and clarity of the information to be collected." This broad solicitation provides an expansive scope for feedback, allowing participants to address everything from the survey’s methodology and the types of data collected to its overall presentation and accessibility.
The notice, formally published in the Federal Register (document number 2026-17875), adheres to the requirements of the federal Paperwork Reduction Act of 1995. This act mandates that federal agencies undergo regular review processes for any efforts to collect information from the public, aiming to minimize the burden on respondents and maximize the utility of the collected data. While such comment periods are a standard part of federal rulemaking, they often receive limited public engagement. This phenomenon means that any well-reasoned and data-supported comments submitted during this window have a genuinely significant chance of capturing the attention of program managers and directly influencing the future direction of NADAC.
For benefits professionals, HR executives, pharmacy owners, and patient advocates, this is a critical juncture. Those who believe NADAC’s current cost figures are either too high or too low, or who identify gaps in the information gathered from pharmacies, now have a formal avenue to articulate their concerns and propose actionable improvements.
Navigating the Complexities of Drug Pricing Benchmarks
The U.S. drug pricing ecosystem is notoriously complex, characterized by multiple layers of intermediaries and various pricing benchmarks. Beyond NADAC, other commonly referenced benchmarks include:
- Average Wholesale Price (AWP): Often referred to as "list price," AWP is a widely used benchmark, but it is not a true reflection of what pharmacies pay. It is typically an inflated price, often used as a starting point for negotiations and discounts. Commercial sources like Red Book provide AWP data.
- Wholesale Acquisition Cost (WAC): This is the manufacturer’s list price for a drug to wholesalers. Like AWP, it does not necessarily reflect the actual price paid by pharmacies after discounts, rebates, or other arrangements.
- Maximum Allowable Cost (MAC): These are price limits set by PBMs or state Medicaid agencies for generic drugs, intended to cap reimbursement for therapeutically equivalent medications.
In this intricate environment, NADAC stands out due to its commitment to reflecting actual acquisition costs. Its free availability and extensive documentation on methodology further distinguish it, making it a preferred data source for drug procurement specialists seeking transparency and accuracy. However, even NADAC has its limitations and areas for potential refinement, which is precisely what the current public comment period aims to address.
Inferred Stakeholder Perspectives and Potential Comments
Given the diverse interests involved in drug pricing, various stakeholders are likely to have distinct perspectives and potential recommendations for the NADAC program:
- Employer Groups and Benefits Advisors: These entities are keenly focused on cost containment and value. They would likely advocate for:
- Enhanced Accuracy: Ensuring NADAC truly reflects the lowest achievable acquisition costs to prevent over-reimbursement.
- Broader Scope: Investigating whether NADAC could incorporate more data points related to specialty drugs, compounded medications, or other high-cost therapies that significantly impact employer plans.
- Timeliness: Ensuring the data is updated frequently enough to reflect dynamic market conditions.
- Integration with PBM Contracts: Recommendations on how NADAC data can be more effectively leveraged in contract negotiations with PBMs to drive down net costs. They might suggest ways for NADAC to provide more granular data that can be used to audit PBM pricing practices.
- Pharmacy Associations and Independent Pharmacies: Pharmacies operate on thin margins and face increasing pressure from PBM reimbursement models. Their likely comments would focus on:
- Comprehensive Cost Capture: Ensuring NADAC accounts for all elements of a pharmacy’s acquisition cost, including shipping, handling, and potential surcharges, beyond just the raw drug price.
- Inclusion of Dispensing Fees: While NADAC focuses on acquisition, pharmacies often struggle with inadequate dispensing fees. While not directly within NADAC’s scope, they might use this platform to highlight the need for accurate total cost recognition, potentially suggesting that NADAC’s utility would be improved if a comprehensive picture of pharmacy costs were available.
- Rural Pharmacy Considerations: Addressing potential disparities in acquisition costs for rural pharmacies compared to larger urban chains, which might face different purchasing dynamics.
- Impact of Direct and Indirect Remuneration (DIR) Fees: While not directly tied to NADAC, pharmacies might raise concerns about how DIR fees (clawbacks from PBMs) effectively raise their net acquisition costs, suggesting that NADAC should strive to reflect the true, post-DIR cost where possible, or at least acknowledge this complex factor.
- Pharmacy Benefit Managers (PBMs): PBMs play a critical role in managing drug benefits and negotiating prices. Their perspective might be more nuanced:
- Validation of Data Sources: PBMs might emphasize the need for NADAC to be cross-referenced with other commercial data sources they utilize to ensure consistency and accuracy across the industry.
- Operational Feasibility: Comments regarding the practicality of implementing changes to the survey process and ensuring the data remains scalable and manageable.
- Market Dynamics: PBMs might highlight the role of their negotiating power and proprietary rebate arrangements, suggesting that NADAC, as an acquisition cost benchmark, only tells one part of the drug pricing story.
- State Medicaid Programs: As primary users of NADAC, states are invested in its accuracy and utility.
- Program Efficiency: Suggestions for streamlining data access and integration into state systems.
- Fair Reimbursement: Ensuring the data allows for equitable reimbursement to pharmacies while protecting state budgets.
- Adaptability: How NADAC can better adapt to rapid changes in drug availability and pricing, especially for new generic entries or supply chain disruptions.
- Consumer and Patient Advocacy Groups: These groups focus on affordability and access. Their input would likely center on:
- Impact on Out-of-Pocket Costs: How improvements to NADAC can directly translate into lower co-pays and deductibles for patients.
- Transparency for Patients: Advocating for greater public accessibility and understandability of how NADAC data influences what patients pay at the pharmacy counter.
- Addressing Disparities: Ensuring that NADAC data helps to mitigate cost disparities that might affect underserved communities.
Historical Context and the Drive for Transparency
The federal government’s engagement in drug cost benchmarking is not new. The establishment of NADAC itself was a response to the need for a more transparent and reliable measure of drug acquisition costs, particularly in the context of Medicaid programs. Prior to NADAC, states often relied on less transparent benchmarks, leading to potential overpayments and inefficiencies. The ongoing debate around drug pricing reform, fueled by concerns over escalating costs and patient affordability, continually underscores the importance of robust data programs like NADAC. Legislative efforts, such as those included in the Inflation Reduction Act of 2022, further highlight a federal commitment to leveraging data and negotiation to control pharmaceutical expenditures, even if those specific provisions primarily target Medicare. NADAC serves as a foundational data layer that informs many of these broader policy discussions.
Broader Impact and Implications for the Future of Healthcare
The outcome of this public comment period and any subsequent revisions to the NADAC program carry significant implications for the entire healthcare ecosystem:
- For Health Plans: A more accurate and comprehensive NADAC could empower employer-sponsored plans to negotiate more effectively with PBMs, leading to lower premiums, reduced administrative costs, and more sustainable benefit offerings. It could also improve the accuracy of financial modeling for future drug expenditures.
- For Pharmacies: Refining NADAC could ensure that pharmacies are reimbursed more fairly, reflecting their true costs of doing business. This is especially crucial for independent pharmacies and those in underserved areas, whose financial viability is often precarious.
- For Patients: Ultimately, improvements to NADAC that lead to more efficient drug pricing and reimbursement could translate into lower out-of-pocket costs for prescription medications, enhancing access and reducing financial burdens for patients.
- For Policy Makers: Enhanced NADAC data provides policymakers with a clearer picture of market dynamics, informing future legislative and regulatory actions aimed at controlling drug costs and promoting transparency.
The current call for comments from CMS is more than a routine bureaucratic exercise; it is an active invitation for stakeholders to contribute to a critical piece of the nation’s drug pricing infrastructure. By actively participating, employers, benefits advisors, and other interested parties have a tangible opportunity to refine a system that profoundly affects healthcare costs, plan design, and patient access to essential medications. The November 2nd deadline serves as a pivotal moment for those seeking to inject greater transparency and efficiency into the complex world of prescription drug acquisition costs.
